Crosstalk between EphA2 and BRaf/CRaf is a Key Determinant of Response to Dasatinib

PURPOSE: EphA2 is an attractive therapeutic target due to its diverse roles in cancer growth and progression. Dasatinib is a multi-kinase inhibitor that targets EphA2 and other kinases. However, reliable predictive markers and a better understanding of the mechanisms of response to this agent are ne...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Huang, Jie, Hu, Wei, Bottsford-Miller, Justin, Liu, Tao, Han, Hee Dong, Zand, Behrouz, Pradeep, Sunila, Roh, Ju-Won, Thanapprapasr, Duangmani, Dalton, Heather J., Pecot, Chad V., Rupaimoole, Rajesh, Lu, Chunhua, Fellman, Bryan, Urbauer, Diana, Kang, Yu, Jennings, Nicholas B., Huang, Li, Deavers, Michael T., Broaddus, Russell, Coleman, Robert L., Sood, Anil K.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2014
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3975695/
https://ncbi.nlm.nih.gov/pubmed/24486585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-2141
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk